The comparison α-blocker+M3 selective anti-muscarinic combined therapy and α-blocker monotherapy

Abstract

Aim Effectiveness and reliability comparison of alpha-blocker monothera-py (doksazosin) and combined alpha-blocker+M3 selective antimuscarinic (doksazosin + darifenacin) treatments on male patients with Benign prostate hyperplasia and accompanying OAB (overactive bladder) symptoms. Methods 101 patients with ages 50 and above who had LUTS (Lower urinary tract symptoms) complaints were included in the study. Patients were randomly organized into two groups. One group had treatment with 4mg doksazosin, the other group had 4mg doksazosin combined with 7.5mg da-rifenacin. Patients were evaluated in accordance with BPH manuals of EUA (European Urology Association) and AUA (American Urology Association). Patients were re-evaluated on 12th week after the treatment. International prostate symptom scores (IPSS), IPSS quality of life scores (IPSS-QoL), maxi-mum urine flow rate (Qmax), average urine flow rates (AFR) and PVR (Post Voiding Residual Volume) data were obtained before and after the treatment from all patients. Results Patients who received combined treatment had experienced considerable drop (P < 0.01) in total IPSS and IPSS-QoL scores compared to monotherapy group. Qmax and and AFR data were found nearly equal (P = 0.732). Considerable increase (P < 0.01) in PVR (>43ml) in combined treatment group was observed. Conclusion Alpha-blocker+M3 selective an-timuscarinic combined treatment is more effective than alpha-blocker mono-therapy on male patients with LUTS secondary to BPH and OAB. However combined treatment causes considerable increase in PVR.

Keywords

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions